Please assess the completion status of the following clinical trial:

Trial Title: Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sex and surgery: male and female patients scheduled for short duration (\< 60 min) distal upper limb surgery under axillary nerve block anaesthesia~2. Age: ≥ 18 years old~3. Body Mass Index (BMI): 18 - 32 kg/m2 inclusive~4. ASA physical status: I-III~5. Informed consent: signed written informed consent before inclusion in the study~6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study~Exclusion Criteria:~1. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study. Contraindications to peripheral nerve block anaesthesia. History of neuromuscular diseases to the upper extremities~2. Axillary status: Axillary local infections, surgical scarring and pathological lymph node enlargement~3. ASA physical status: IV-V~4. Further anaesthesia: Patients anticipated to be requiring further anaesthesia (general or local anaesthesia)~5. Chronic pain syndromes: Patients with chronic pain syndromes (taking opioids, antidepressants, anticonvulsant agents)~6. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations ingredients; ascertained or presumptive hypersensitivity to the amide and ester-type anaesthetics~7. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric diseases, sepsis, blood coagulation disorders, insulin dependent diabetes mellitus, terminal kidney failure~8. Medications: Medication known to interfere with the extent of regional blocks (see chloroprocaine and ropivacaine SmPCs) for 2 weeks before the start of the study. Hormonal contraceptives for females will be allowed~9. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study~10. Drug, alcohol: history of drug or alcohol abuse~11. Pregnancy: missing or positive pregnancy test at screening, pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroprocaine HCl 2% (20 mg/mL) (Type: EXPERIMENTAL): Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
- Ropivacaine 0.75% (7.5 mg/mL) (Type: ACTIVE_COMPARATOR): Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).